WO1993015737A1 - Compositions for nasal administration containing polar metabolites of opioid analgesics - Google Patents
Compositions for nasal administration containing polar metabolites of opioid analgesics Download PDFInfo
- Publication number
- WO1993015737A1 WO1993015737A1 PCT/GB1993/000228 GB9300228W WO9315737A1 WO 1993015737 A1 WO1993015737 A1 WO 1993015737A1 GB 9300228 W GB9300228 W GB 9300228W WO 9315737 A1 WO9315737 A1 WO 9315737A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- morphine
- microspheres
- glucuronide
- composition according
- sulphate
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Otolaryngology (AREA)
- Emergency Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DK93917408T DK0625044T3 (en) | 1992-02-05 | 1993-02-04 | Nasal administration compositions containing polar metabolites of opoid analgesics |
DE69321458T DE69321458T2 (en) | 1992-02-05 | 1993-02-04 | PHARMACEUTICAL PREPARATIONS FOR NASAL ADMINISTRATION CONTAINING POLAR METABOLIC METAL PRODUCTS OF OPIATE ANALGETICS |
EP93917408A EP0625044B1 (en) | 1992-02-05 | 1993-02-04 | Compositions for nasal administration containing polar metabolites of opioid analgesics |
AU34580/93A AU665806B2 (en) | 1992-02-05 | 1993-02-04 | Compositions for nasal administration containing polar metabolites of opioid analgesics |
CA002127805A CA2127805C (en) | 1992-02-05 | 1993-02-04 | Composition for nasal administration |
GB9413102A GB2277682B (en) | 1992-02-05 | 1993-02-04 | Compositions for nasal administration containing polar metabolites of opioid analgesics |
US08/256,431 US5629011A (en) | 1992-02-05 | 1993-02-04 | Composition for nasal administration |
JP51386993A JP3958352B2 (en) | 1992-02-05 | 1993-02-04 | Composition for nasal administration containing polar metabolite of opioid analgesic |
NO942787A NO306283B1 (en) | 1992-02-05 | 1994-07-27 | Pharmaceutical composition for nasal administration comprising polar morphine metabolites |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB929202464A GB9202464D0 (en) | 1992-02-05 | 1992-02-05 | Composition for nasal administration |
GB9202464.5 | 1992-02-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1993015737A1 true WO1993015737A1 (en) | 1993-08-19 |
Family
ID=10709891
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB1993/000228 WO1993015737A1 (en) | 1992-02-05 | 1993-02-04 | Compositions for nasal administration containing polar metabolites of opioid analgesics |
Country Status (12)
Country | Link |
---|---|
US (1) | US5629011A (en) |
EP (1) | EP0625044B1 (en) |
JP (1) | JP3958352B2 (en) |
AT (1) | ATE171872T1 (en) |
AU (1) | AU665806B2 (en) |
CA (1) | CA2127805C (en) |
DE (1) | DE69321458T2 (en) |
DK (1) | DK0625044T3 (en) |
ES (1) | ES2123660T3 (en) |
GB (2) | GB9202464D0 (en) |
NO (1) | NO306283B1 (en) |
WO (1) | WO1993015737A1 (en) |
Cited By (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994022445A2 (en) * | 1993-03-26 | 1994-10-13 | Merkus Franciscus W H M | Pharmaceutical compositions for intranasal administration of dihydroergotamine, apomorphine and morphine |
GB2282758A (en) * | 1993-08-23 | 1995-04-19 | Euro Celtique Sa | Oral morphine-6-glucuronide compositions |
WO1995020966A1 (en) * | 1994-02-07 | 1995-08-10 | Lts Lohmann Therapie-Systeme Gmbh | Pharmaceutical composition for systemic transdermal administration containing the active agent morphine-6-glucuronide |
WO1996005810A1 (en) * | 1994-08-20 | 1996-02-29 | Danbiosyst Uk Limited | Drug delivery composition containing chitosan or derivative thereof having a defined z. potential |
US5543434A (en) * | 1994-02-25 | 1996-08-06 | Weg; Stuart L. | Nasal administration of ketamine to manage pain |
WO1997035562A1 (en) * | 1996-03-23 | 1997-10-02 | Danbiosyst Uk Limited | Polysaccharide microspheres for the pulmonary delivery of drugs |
US5679714A (en) * | 1995-06-07 | 1997-10-21 | Weg; Stuart L. | Administration of ketamine for detoxification and treatment of tobacco addiction |
FR2771929A1 (en) * | 1997-12-09 | 1999-06-11 | Biovector Therapeutics | USE IN A PHARMACEUTICAL COMPOSITION FOR NASAL ADMINISTRATION OF HYDROPHILIC PARTICLES FOR THE DELIVERY OF ACTIVE AGENTS TO THE CENTRAL NERVOUS SYSTEM |
US6017963A (en) * | 1995-11-14 | 2000-01-25 | Euro-Celtique, S.A. | Formulation for intranasal administration |
WO2000021515A2 (en) * | 1998-10-14 | 2000-04-20 | New Millennium Pharmaceutical Research, Inc. | Intranasal codeine for the rapid suppression of cough and rapid relief of pain |
WO2000033810A1 (en) * | 1998-12-09 | 2000-06-15 | Biovector Therapeutics (S.A.) | Use of vitamin b12 in a nasal composition for delivering active agents to the central nervous system |
WO2000062757A1 (en) * | 1999-04-19 | 2000-10-26 | Britannia Pharmaceuticals Limited | Composition containing opioid antagonists and spray dispenser |
US6207197B1 (en) | 1997-05-24 | 2001-03-27 | West Pharmaceutical Services Drug Delivery & Clinical Research Centre Limited | Gastroretentive controlled release microspheres for improved drug delivery |
US6248789B1 (en) | 1996-08-29 | 2001-06-19 | Stuart L. Weg | Administration of ketamine to manage pain and to reduce drug dependency |
WO2003080021A2 (en) * | 2002-03-19 | 2003-10-02 | Ionix Pharmaceuticals Limited | Formulation comprising buprenorphine |
EP1224188B1 (en) * | 1999-10-20 | 2007-01-17 | Archimedes Development Limited | Nasal delivery composition comprising the methane sulphonate salt of morphine and chitosan |
WO2008091588A1 (en) | 2007-01-22 | 2008-07-31 | Targacept, Inc. | Intranasal, buccal, and sublingual administration of metanicotine analogs |
US7498038B2 (en) | 2001-08-16 | 2009-03-03 | Cmp Therapeutics Limited | Chitin microparticles and their medical uses |
US8198240B2 (en) | 2005-08-26 | 2012-06-12 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for treatment of headaches by administration of oxytocin |
US8889176B2 (en) | 2003-01-10 | 2014-11-18 | Depomed, Inc. | Method of managing or treating pain |
US9629894B2 (en) | 2015-01-07 | 2017-04-25 | Trigemina, Inc. | Magnesium-containing oxytocin formulations and methods of use |
Families Citing this family (96)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1247472B (en) * | 1991-05-31 | 1994-12-17 | Fidia Spa | PROCESS FOR THE PREPARATION OF MICROSPHERES CONTAINING BIOLOGICALLY ACTIVE COMPONENTS. |
US5266331A (en) * | 1991-11-27 | 1993-11-30 | Euroceltique, S.A. | Controlled release oxycodone compositions |
US5478577A (en) * | 1993-11-23 | 1995-12-26 | Euroceltique, S.A. | Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level |
US20080075781A1 (en) * | 1992-11-25 | 2008-03-27 | Purdue Pharma Lp | Controlled release oxycodone compositions |
US20070275062A1 (en) * | 1993-06-18 | 2007-11-29 | Benjamin Oshlack | Controlled release oxycodone compositions |
US7740881B1 (en) | 1993-07-01 | 2010-06-22 | Purdue Pharma Lp | Method of treating humans with opioid formulations having extended controlled release |
IL110014A (en) * | 1993-07-01 | 1999-11-30 | Euro Celtique Sa | Solid controlled-release oral dosage forms of opioid analgesics |
US5879705A (en) * | 1993-07-27 | 1999-03-09 | Euro-Celtique S.A. | Sustained release compositions of morphine and a method of preparing pharmaceutical compositions |
WO1996002275A1 (en) * | 1994-07-20 | 1996-02-01 | Toyama Chemical Co., Ltd. | Sustained-release oral ointment |
GB9419979D0 (en) * | 1994-10-04 | 1994-11-16 | Medeva Holdings Bv | Vaccine compositions |
GB9519363D0 (en) | 1995-09-22 | 1995-11-22 | Euro Celtique Sa | Pharmaceutical formulation |
GB9522351D0 (en) * | 1995-11-01 | 1996-01-03 | Medeva Holdings Bv | Vaccine compositions |
GB9525083D0 (en) * | 1995-12-07 | 1996-02-07 | Danbiosyst Uk | Vaccine compositions |
US5976573A (en) * | 1996-07-03 | 1999-11-02 | Rorer Pharmaceutical Products Inc. | Aqueous-based pharmaceutical composition |
US6403602B1 (en) * | 1997-02-20 | 2002-06-11 | The University Of Kentucky Research Foundation | Morphine-6-sulfate analogues and their use for the treatment of pain |
JP2005281315A (en) * | 1997-07-02 | 2005-10-13 | Aventis Pharmaceuticals Holdings Inc | Aqueous pharmacological composition |
CA2296620A1 (en) * | 1997-07-18 | 1999-01-28 | Kris P. Antonsen | Methods of removing residual solvent from nasal drug delivery compositions |
US6391452B1 (en) | 1997-07-18 | 2002-05-21 | Bayer Corporation | Compositions for nasal drug delivery, methods of making same, and methods of removing residual solvent from pharmaceutical preparations |
JP4234803B2 (en) * | 1997-10-27 | 2009-03-04 | 久光製薬株式会社 | Pharmaceutical composition with controlled drug release rate |
US7070799B1 (en) * | 1998-02-10 | 2006-07-04 | Generex Pharmaceuticals, Inc. | Method for administering insulin to the buccal region |
US6221378B1 (en) | 1998-02-10 | 2001-04-24 | Generex Pharmaceuticals Incorporated | Mixed micellar delivery system and method of preparation |
US6017545A (en) * | 1998-02-10 | 2000-01-25 | Modi; Pankaj | Mixed micellar delivery system and method of preparation |
US6350458B1 (en) | 1998-02-10 | 2002-02-26 | Generex Pharmaceuticals Incorporated | Mixed micellar drug deliver system and method of preparation |
AU753278B2 (en) * | 1998-02-25 | 2002-10-10 | Abbott Laboratories | Butorphanol sustained release formulations |
US6150420A (en) * | 1998-06-01 | 2000-11-21 | Theramax, Inc. | Method for enhanced brain delivery of bupropion |
US6806294B2 (en) | 1998-10-15 | 2004-10-19 | Euro-Celtique S.A. | Opioid analgesic |
US7087215B2 (en) * | 1998-12-21 | 2006-08-08 | Generex Pharmaceuticals Incorporated | Methods of administering and enhancing absorption of pharmaceutical agents |
US6375975B1 (en) | 1998-12-21 | 2002-04-23 | Generex Pharmaceuticals Incorporated | Pharmaceutical compositions for buccal and pulmonary application |
US6451286B1 (en) | 1998-12-21 | 2002-09-17 | Generex Pharmaceuticals Incorporated | Pharmaceutical compositions for buccal and pulmonary administration comprising an alkali metal alkyl sulfate and at least three micelle-forming compounds |
US6849263B2 (en) * | 1998-12-21 | 2005-02-01 | Generex Pharmaceutical Incorporated | Pharmaceutical compositions for buccal delivery of pain relief medications |
ES2197792B1 (en) | 1999-06-16 | 2005-05-01 | Nastech Pharmaceutical Co., Inc. | PHARMACEUTICAL FORMULATIONS CONTAINING INTRANASAL MORPHINE. |
WO2000076477A1 (en) * | 1999-06-16 | 2000-12-21 | Nastech Pharmaceutical Co., Inc. | Methods and compositions for treating breakthrough pain |
US6225343B1 (en) | 1999-06-16 | 2001-05-01 | Nastech Pharmaceutical Company, Inc. | Compositions and methods comprising morphine gluconate |
US6863896B1 (en) * | 1999-10-26 | 2005-03-08 | Chiron Corporation | Plant lectins as mucosal adjuvants |
NZ529928A (en) | 1999-10-29 | 2005-10-28 | Euro Celtique Sa | Controlled release hydrocodone formulations |
US10179130B2 (en) | 1999-10-29 | 2019-01-15 | Purdue Pharma L.P. | Controlled release hydrocodone formulations |
CA2400578C (en) * | 2000-02-08 | 2007-01-02 | Euro-Celtique, S.A. | Controlled-release compositions containing opioid agonist and antagonist |
HU229705B1 (en) * | 2000-02-08 | 2014-05-28 | Euro Celtique Sa | Tamper-resistant oral opioid agonist formulations |
US6716449B2 (en) * | 2000-02-08 | 2004-04-06 | Euro-Celtique S.A. | Controlled-release compositions containing opioid agonist and antagonist |
US20040115133A1 (en) * | 2000-05-10 | 2004-06-17 | Wermeling Daniel P. | Intranasal opioid compositions |
US6610271B2 (en) * | 2000-05-10 | 2003-08-26 | University Of Kentucky Research Foundation | System and method for intranasal administration of lorazepam |
US20060083691A1 (en) * | 2000-05-10 | 2006-04-20 | Wermeling Daniel P | Intranasal opioid compositions, delivery devices and methods of using same |
US20020013331A1 (en) * | 2000-06-26 | 2002-01-31 | Williams Robert O. | Methods and compositions for treating pain of the mucous membrane |
FR2811227A1 (en) * | 2000-07-07 | 2002-01-11 | Philippe Maincent | PARTICULATE VECTORS FOR IMPROVING ORAL ABSORPTION OF ACTIVE PRINCIPLES |
US8257744B2 (en) * | 2000-07-07 | 2012-09-04 | Laboratorios Farmacéuticos Rovi, S.A. | Pharmaceutical forms for the release of active compounds |
JP2004505730A (en) * | 2000-08-15 | 2004-02-26 | ユニバーシティ オブ ケンタッキー リサーチ ファウンデーション | Programmable multi-dose intranasal drug delivery device |
KR101045144B1 (en) | 2000-10-30 | 2011-06-30 | 유로-셀티크 소시에떼 아노뉨 | Controlled release hydrocodone formulations |
US20040176359A1 (en) * | 2001-02-20 | 2004-09-09 | University Of Kentucky Research Foundation | Intranasal Benzodiazepine compositions |
US20030044356A1 (en) * | 2001-04-20 | 2003-03-06 | Jin Auh | Composition for nasal solution sprays having effective component of 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-4H-carbazol-4-one) |
UA81224C2 (en) * | 2001-05-02 | 2007-12-25 | Euro Celtic S A | Dosage form of oxycodone and use thereof |
US20110104214A1 (en) | 2004-04-15 | 2011-05-05 | Purdue Pharma L.P. | Once-a-day oxycodone formulations |
US8329216B2 (en) * | 2001-07-06 | 2012-12-11 | Endo Pharmaceuticals Inc. | Oxymorphone controlled release formulations |
CN1610551A (en) * | 2001-07-06 | 2005-04-27 | 恩德制药公司 | Parenteral administration of 6-hydroxy-oxymorphone for use as an analgesic |
WO2003026743A2 (en) * | 2001-09-26 | 2003-04-03 | Penwest Pharmaceuticals Company | Opioid formulations having reduced potential for abuse |
US20140271788A1 (en) | 2013-03-15 | 2014-09-18 | Monosol Rx, Llc | Sublingual and buccal film compositions |
US20060014695A1 (en) * | 2002-02-01 | 2006-01-19 | Hamidreza Ghandehari | Hpma-polyamine conjugates and uses therefore |
US20040077540A1 (en) * | 2002-06-28 | 2004-04-22 | Nastech Pharmaceutical Company Inc. | Compositions and methods for modulating physiology of epithelial junctional adhesion molecules for enhanced mucosal delivery of therapeutic compounds |
JP2006021996A (en) * | 2002-07-04 | 2006-01-26 | Dainippon Sumitomo Pharma Co Ltd | Conjugated substance of substituted hydroxypyridine compound |
DK1551372T3 (en) * | 2002-09-20 | 2018-07-23 | Alpharma Pharmaceuticals Llc | SEQUERATION SUBSTANCES AND RELATED COMPOSITIONS AND PROCEDURES |
DE10248601B4 (en) * | 2002-10-17 | 2006-05-24 | Goldstein, Naum, Dr.habil.nat. | Pharmaceutical agent for endonasal administration in the treatment of diseases and disorders of the central nervous system |
US7445769B2 (en) * | 2002-10-31 | 2008-11-04 | Cadbury Adams Usa Llc | Compositions for removing stains from dental surfaces and methods of making and using the same |
GB0302738D0 (en) * | 2003-02-06 | 2003-03-12 | Advanced Biopolymers As | Composition |
CN100575955C (en) * | 2003-04-30 | 2009-12-30 | 纳斯泰克制药公司 | Close albumen do not express label as metastases |
CA2524286A1 (en) * | 2003-05-01 | 2004-11-18 | West Pharmaceutical Services Drug Delivery & Clinical Research Centre Li Mited | Nasal administration of the lh-rh analog leuprolide |
US20060263350A1 (en) * | 2003-09-26 | 2006-11-23 | Fairfield Clinical Trials Llc | Combination antihistamine medication |
US7968122B2 (en) * | 2003-12-10 | 2011-06-28 | Adventrx Pharmaceuticals, Inc. | Anti-viral pharmaceutical compositions |
US20050129679A1 (en) * | 2003-12-15 | 2005-06-16 | Nastech Pharmaceutical Company Inc. | Method for opening tight junctions |
GB0400804D0 (en) | 2004-01-14 | 2004-02-18 | Innoscience Technology Bv | Pharmaceutical compositions |
US20050175679A1 (en) * | 2004-02-10 | 2005-08-11 | Michael Moshman | Controlled release formulations |
GB0403938D0 (en) * | 2004-02-21 | 2004-03-24 | West Pharm Serv Drug Res Ltd | Chitosan containing solution |
US20050283004A1 (en) * | 2004-06-18 | 2005-12-22 | Hopax Chemicals Manufacturing Co., Ltd. | Alkylsulfonated polyaminosaccharides |
GB0416328D0 (en) * | 2004-07-21 | 2004-08-25 | Univ Cardiff | Use of dry powder compositions for pulmonary delivery |
US7641892B2 (en) * | 2004-07-29 | 2010-01-05 | Cadburry Adams USA, LLC | Tooth whitening compositions and delivery systems therefor |
US7115561B2 (en) * | 2004-09-22 | 2006-10-03 | Patterson James A | Medicament composition and method of administration |
US20060183724A1 (en) * | 2005-02-03 | 2006-08-17 | Diliberti Charles E | Compositions of unconjugated estrogens and methods for their use |
US20070212414A1 (en) * | 2006-03-08 | 2007-09-13 | Penwest Pharmaceuticals Co. | Ethanol-resistant sustained release formulations |
CN105853394A (en) * | 2006-03-30 | 2016-08-17 | 恩根尼公司 | Non-viral compositions and methods for transfecting gut cells in vivo |
CN101677963B (en) | 2006-06-19 | 2012-05-30 | 奥尔制药公司 | Pharmaceutical compositions |
US20080075771A1 (en) * | 2006-07-21 | 2008-03-27 | Vaughn Jason M | Hydrophilic opioid abuse deterrent delivery system using opioid antagonists |
CA2665726C (en) * | 2006-10-11 | 2016-04-19 | Alpharma, Inc. | Pharmaceutical compositions |
US20080275030A1 (en) | 2007-01-19 | 2008-11-06 | Sveinbjorn Gizurarson | Methods and Compositions for the Delivery of a Therapeutic Agent |
US20090124650A1 (en) * | 2007-06-21 | 2009-05-14 | Endo Pharmaceuticals, Inc. | Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instructions on Effects of Alcohol |
US8802156B2 (en) | 2007-11-14 | 2014-08-12 | Laboratorios Farmacéuticos Rovi, S.A. | Pharmaceutical forms for the release of active compounds |
US20090196890A1 (en) * | 2007-12-17 | 2009-08-06 | Alpharma Pharmaceuticals, Llc | Pharmaceutical compositions |
US8623418B2 (en) | 2007-12-17 | 2014-01-07 | Alpharma Pharmaceuticals Llc | Pharmaceutical composition |
AR086391A1 (en) | 2011-05-13 | 2013-12-11 | Euro Celtique Sa | INTRANASAL PHARMACEUTICAL DOSAGE FORMS THAT INCLUDE NALOXONE |
US11413239B2 (en) | 2011-07-20 | 2022-08-16 | Torrent Pharmaceuticals Ltd. | Pharmaceutical composition of tapentadol for nasal administration |
US10472334B2 (en) | 2014-03-14 | 2019-11-12 | The University Of North Carolina At Chapel Hill | Small molecules for inhibiting male fertility |
FR3032353B1 (en) | 2015-02-06 | 2017-03-10 | Jacques Seguin | PHARMACEUTICAL COMPOSITION AND DEVICE FOR THE TREATMENT OF PAIN |
AU2017345767A1 (en) * | 2016-10-21 | 2019-05-16 | Somniferum Labs LLC | Apparatus for controlled delivery of opioid and other medications |
RS65027B1 (en) | 2017-01-11 | 2024-01-31 | Torrent Pharmaceuticals Ltd | Tapentadol nasal composition |
US10292948B2 (en) | 2017-01-11 | 2019-05-21 | Torrent Pharmaceuticals Limited | Tapentadol nasal composition |
US10639294B2 (en) | 2018-10-02 | 2020-05-05 | Janssen Pharmaceutica Nv | Pharmaceutical compositions comprising a hydroxyethylquercetin glucuronide metabolite |
US11304968B2 (en) | 2018-11-16 | 2022-04-19 | Janssen Pharmaceutica Nv | Pharmaceutical compositions comprising a hydroxyethylquercetin glucuronide |
CN110257025B (en) * | 2019-07-03 | 2020-07-03 | 中国石油大学(华东) | Cyclodextrin microsphere ultra-high temperature fluid loss additive for water-based drilling fluid, preparation method thereof, water-based drilling fluid and application thereof |
US20230372327A1 (en) * | 2020-10-15 | 2023-11-23 | Pharmbiotest Poland Sp. z o. o. | Pharmaceutical composition based on nalbuphine and/or its salts for nasal administration |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1982003768A1 (en) * | 1981-04-28 | 1982-11-11 | Kentucky Univ | Novel method of administering narcotic antagonists and analgesics and novel dosage forms containing same |
EP0205282A2 (en) * | 1985-06-11 | 1986-12-17 | Euroceltique S.A. | Oral pharmaceutical composition |
DE3602370A1 (en) * | 1986-01-27 | 1987-08-06 | Chrubasik Sigrun | Use of analgesics by inhalation |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8918879D0 (en) * | 1989-08-18 | 1989-09-27 | Danbiosyst Uk | Pharmaceutical compositions |
DE69122464T2 (en) * | 1990-03-30 | 1997-02-20 | Yasunori Morimoto | TRANSDERMAL ABSORBABLE AGENT WITH MORPHINE HYDROCHLORIDE |
FR2665357B1 (en) * | 1990-07-31 | 1995-03-31 | Aiache Jean Marc | PROCESS FOR THE PREPARATION OF A BIO-ADHESIVE GALENIC FORM AND GALENIC FORM THUS PREPARED. |
EP0638081A1 (en) * | 1992-04-13 | 1995-02-15 | The Regents Of The University Of Minnesota | Delta opioid receptor-selective benzylidene-substituted morphinans for the treatment of alcohol abuse |
-
1992
- 1992-02-05 GB GB929202464A patent/GB9202464D0/en active Pending
-
1993
- 1993-02-04 DK DK93917408T patent/DK0625044T3/en active
- 1993-02-04 WO PCT/GB1993/000228 patent/WO1993015737A1/en active IP Right Grant
- 1993-02-04 EP EP93917408A patent/EP0625044B1/en not_active Expired - Lifetime
- 1993-02-04 AT AT93917408T patent/ATE171872T1/en active
- 1993-02-04 AU AU34580/93A patent/AU665806B2/en not_active Expired
- 1993-02-04 GB GB9413102A patent/GB2277682B/en not_active Revoked
- 1993-02-04 DE DE69321458T patent/DE69321458T2/en not_active Expired - Lifetime
- 1993-02-04 CA CA002127805A patent/CA2127805C/en not_active Expired - Lifetime
- 1993-02-04 ES ES93917408T patent/ES2123660T3/en not_active Expired - Lifetime
- 1993-02-04 US US08/256,431 patent/US5629011A/en not_active Expired - Lifetime
- 1993-02-04 JP JP51386993A patent/JP3958352B2/en not_active Expired - Lifetime
-
1994
- 1994-07-27 NO NO942787A patent/NO306283B1/en not_active IP Right Cessation
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1982003768A1 (en) * | 1981-04-28 | 1982-11-11 | Kentucky Univ | Novel method of administering narcotic antagonists and analgesics and novel dosage forms containing same |
EP0205282A2 (en) * | 1985-06-11 | 1986-12-17 | Euroceltique S.A. | Oral pharmaceutical composition |
DE3602370A1 (en) * | 1986-01-27 | 1987-08-06 | Chrubasik Sigrun | Use of analgesics by inhalation |
Cited By (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5756483A (en) * | 1993-03-26 | 1998-05-26 | Merkus; Franciscus W. H. M. | Pharmaceutical compositions for intranasal administration of apomorphine |
WO1994022445A3 (en) * | 1993-03-26 | 1995-01-05 | Franciscus W H M Merkus | Pharmaceutical compositions for intranasal administration of dihydroergotamine, apomorphine and morphine |
US5942251A (en) * | 1993-03-26 | 1999-08-24 | Merkus; Franciscus W. H. M. | Pharmaceutical compositions for intranasal administration of dihydroergotamine |
WO1994022445A2 (en) * | 1993-03-26 | 1994-10-13 | Merkus Franciscus W H M | Pharmaceutical compositions for intranasal administration of dihydroergotamine, apomorphine and morphine |
GB2282758A (en) * | 1993-08-23 | 1995-04-19 | Euro Celtique Sa | Oral morphine-6-glucuronide compositions |
WO1995020966A1 (en) * | 1994-02-07 | 1995-08-10 | Lts Lohmann Therapie-Systeme Gmbh | Pharmaceutical composition for systemic transdermal administration containing the active agent morphine-6-glucuronide |
US5989582A (en) * | 1994-02-25 | 1999-11-23 | Weg; Stuart L. | Administration of ketamine for detoxification and to treat substance addiction, and compositions therefor |
US5543434A (en) * | 1994-02-25 | 1996-08-06 | Weg; Stuart L. | Nasal administration of ketamine to manage pain |
US5840341A (en) * | 1994-08-20 | 1998-11-24 | Danbiosyst Uk Limited | Drug delivery composition containing chitosan or derivative thereof having a defined z. potential |
GB2305124B (en) * | 1994-08-20 | 1998-11-18 | Danbiosyst Uk | Drug delivery composition containing chitosan or derivative thereof having a defined z.potential |
GB2305124A (en) * | 1994-08-20 | 1997-04-02 | Danbiosyst Uk | Drug delivery composition containing chitosan or derivative thereof having a defined z.potential |
WO1996005810A1 (en) * | 1994-08-20 | 1996-02-29 | Danbiosyst Uk Limited | Drug delivery composition containing chitosan or derivative thereof having a defined z. potential |
US5679714A (en) * | 1995-06-07 | 1997-10-21 | Weg; Stuart L. | Administration of ketamine for detoxification and treatment of tobacco addiction |
US6017963A (en) * | 1995-11-14 | 2000-01-25 | Euro-Celtique, S.A. | Formulation for intranasal administration |
GB2325162A (en) * | 1996-03-23 | 1998-11-18 | Danbiosyst Uk | Polysaccharide microspheres for the pulmonary delivery of drugs |
GB2325162B (en) * | 1996-03-23 | 2000-02-23 | Danbiosyst Uk | Polysaccharide microspheres for the pulmonary delivery of drugs |
WO1997035562A1 (en) * | 1996-03-23 | 1997-10-02 | Danbiosyst Uk Limited | Polysaccharide microspheres for the pulmonary delivery of drugs |
US6248789B1 (en) | 1996-08-29 | 2001-06-19 | Stuart L. Weg | Administration of ketamine to manage pain and to reduce drug dependency |
US6207197B1 (en) | 1997-05-24 | 2001-03-27 | West Pharmaceutical Services Drug Delivery & Clinical Research Centre Limited | Gastroretentive controlled release microspheres for improved drug delivery |
WO1999029295A1 (en) * | 1997-12-09 | 1999-06-17 | Biovector Therapeutics (S.A.) | Use in a pharmaceutical composition to be administered through the nose of hydrophilic particles for delivering active agents to the central nervous system |
FR2771929A1 (en) * | 1997-12-09 | 1999-06-11 | Biovector Therapeutics | USE IN A PHARMACEUTICAL COMPOSITION FOR NASAL ADMINISTRATION OF HYDROPHILIC PARTICLES FOR THE DELIVERY OF ACTIVE AGENTS TO THE CENTRAL NERVOUS SYSTEM |
WO2000021515A2 (en) * | 1998-10-14 | 2000-04-20 | New Millennium Pharmaceutical Research, Inc. | Intranasal codeine for the rapid suppression of cough and rapid relief of pain |
WO2000021515A3 (en) * | 1998-10-14 | 2000-09-28 | New Millennium Pharmaceutical | Intranasal codeine for the rapid suppression of cough and rapid relief of pain |
US6608073B1 (en) | 1998-10-14 | 2003-08-19 | New Millennium Pharmaceutical Research, Inc. | Intranasal codeine for the rapid suppression of cough and rapid relief of pain |
WO2000033810A1 (en) * | 1998-12-09 | 2000-06-15 | Biovector Therapeutics (S.A.) | Use of vitamin b12 in a nasal composition for delivering active agents to the central nervous system |
FR2787029A1 (en) * | 1998-12-09 | 2000-06-16 | Biovector Therapeutics | USE IN A PHARMACEUTICAL COMPOSITION FOR NASAL ADMINISTRATION OF VITAMIN B12 FOR THE DELIVERY OF ACTIVE AGENTS TO THE CENTRAL NERVOUS SYSTEM |
WO2000062757A1 (en) * | 1999-04-19 | 2000-10-26 | Britannia Pharmaceuticals Limited | Composition containing opioid antagonists and spray dispenser |
EP1224188B1 (en) * | 1999-10-20 | 2007-01-17 | Archimedes Development Limited | Nasal delivery composition comprising the methane sulphonate salt of morphine and chitosan |
US8551501B2 (en) | 2001-08-16 | 2013-10-08 | Mucovax Inc. | Chitin microparticles and their medical uses |
US7498038B2 (en) | 2001-08-16 | 2009-03-03 | Cmp Therapeutics Limited | Chitin microparticles and their medical uses |
WO2003080021A3 (en) * | 2002-03-19 | 2003-12-31 | Ionix Pharmaceuticals Ltd | Formulation comprising buprenorphine |
WO2003080022A3 (en) * | 2002-03-19 | 2004-05-13 | Ionix Pharmaceuticals Ltd | Analgesics for nasal administration |
GB2397016A (en) * | 2002-03-19 | 2004-07-14 | Ionix Pharmaceuticals Ltd | Intranasal analgesic composition comprising buprenorphine, & preferably chitosan or partially esterified pectin |
GB2397016B (en) * | 2002-03-19 | 2004-10-27 | Ionix Pharmaceuticals Ltd | Intranasal analgesic composition containing buprenorphine |
WO2003080021A2 (en) * | 2002-03-19 | 2003-10-02 | Ionix Pharmaceuticals Limited | Formulation comprising buprenorphine |
WO2003080022A2 (en) * | 2002-03-19 | 2003-10-02 | Ionix Pharmaceuticals Limited | Analgesics for nasal administration |
US7666876B2 (en) | 2002-03-19 | 2010-02-23 | Vernalis (R&D) Limited | Buprenorphine formulations for intranasal delivery |
US8889176B2 (en) | 2003-01-10 | 2014-11-18 | Depomed, Inc. | Method of managing or treating pain |
US9078814B2 (en) | 2003-01-10 | 2015-07-14 | Depomed, Inc. | Intranasal spray device containing pharmaceutical composition |
US9814705B2 (en) | 2003-01-10 | 2017-11-14 | Depomed, Inc. | Intranasal spray device containing pharmaceutical composition |
US8202838B2 (en) | 2005-08-26 | 2012-06-19 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for treatment of headaches by administration of oxytocin |
US8252745B2 (en) | 2005-08-26 | 2012-08-28 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for treatment of headaches by administration of oxytocin |
US8258096B2 (en) | 2005-08-26 | 2012-09-04 | The Board Of Trustees Of The Leland Stanford Junior University | Therapy procedure for drug delivery for trigeminal pain |
US8501691B2 (en) | 2005-08-26 | 2013-08-06 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for treatment of headaches by administration of oxytocin |
US8198240B2 (en) | 2005-08-26 | 2012-06-12 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for treatment of headaches by administration of oxytocin |
WO2008091588A1 (en) | 2007-01-22 | 2008-07-31 | Targacept, Inc. | Intranasal, buccal, and sublingual administration of metanicotine analogs |
US9629894B2 (en) | 2015-01-07 | 2017-04-25 | Trigemina, Inc. | Magnesium-containing oxytocin formulations and methods of use |
US11389473B2 (en) | 2015-01-07 | 2022-07-19 | Tonix Pharmaceuticals Holding Corp. | Magnesium-containing oxytocin formulations and methods of use |
Also Published As
Publication number | Publication date |
---|---|
GB9413102D0 (en) | 1994-08-31 |
NO942787D0 (en) | 1994-07-27 |
AU665806B2 (en) | 1996-01-18 |
ATE171872T1 (en) | 1998-10-15 |
CA2127805C (en) | 2004-03-30 |
NO942787L (en) | 1994-07-27 |
NO306283B1 (en) | 1999-10-18 |
GB9202464D0 (en) | 1992-03-18 |
GB2277682A (en) | 1994-11-09 |
US5629011A (en) | 1997-05-13 |
CA2127805A1 (en) | 1993-08-19 |
JP3958352B2 (en) | 2007-08-15 |
DE69321458T2 (en) | 1999-03-18 |
EP0625044A1 (en) | 1994-11-23 |
DE69321458D1 (en) | 1998-11-12 |
EP0625044B1 (en) | 1998-10-07 |
ES2123660T3 (en) | 1999-01-16 |
GB2277682B (en) | 1995-12-20 |
DK0625044T3 (en) | 1999-06-21 |
AU3458093A (en) | 1993-09-03 |
JPH07503481A (en) | 1995-04-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0625044B1 (en) | Compositions for nasal administration containing polar metabolites of opioid analgesics | |
JP4728580B2 (en) | Formulation | |
JP4754067B2 (en) | Composition for nasal administration | |
EP0776195B1 (en) | Drug delivery composition containing chitosan or derivative thereof having a defined z. potential | |
US5770559A (en) | Solubilization of pharmaceutical substances in an organic solvent and preparation of pharmaceutical powders using the same | |
JP2002512947A (en) | Pharmaceutical composition containing factor VIII and neutral liposomes | |
JP2001504828A (en) | Method of preparing a controlled release system | |
JPH07179363A (en) | Production of microsphere containing biologically active component | |
JP2001515862A (en) | Controlled release microsphere delivery system | |
JPH05103838A (en) | System for administering drug including interaction between protein or polypeptide and biologically decomposable hydrophobic polymer | |
WO1999033491A1 (en) | Sustained release medicinal compositions | |
NO178564B (en) | Process for preparing a system for administering active drugs through mucosa | |
JP2002543110A (en) | Amplification of folate-mediated targeting to tumor cells using nanoparticles | |
JP2002528518A (en) | Mucus-adhering polymer, its use and its production | |
Borodkin | Ion-exchange resin delivery systems | |
CN105534905A (en) | Multi-vesicular liposome containing entecavir and preparation method of multi-vesicular liposome | |
JP2921988B2 (en) | Intranasal anti-migraine composition | |
CA2928697C (en) | Delivery of drugs | |
JP2001510811A (en) | Polymer-based drug composition for delivering a bioactive substance to a target | |
CN116531486A (en) | Preparation method of octreotide-loaded human serum albumin nanoparticle | |
CA2197062C (en) | Drug delivery composition containing chitosan or derivative thereof having a defined z. potential | |
Oberholzer | Peroral and nasal delivery of insulin with PheroidTM technology | |
Ludwig et al. | Abstracts of papers biopharmaceutical meeting | |
ZA200407540B (en) | Formulation comprising buprenorphine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA FI GB JP NO US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1993917408 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2127805 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 08256431 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 1993917408 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1993917408 Country of ref document: EP |